239 related articles for article (PubMed ID: 32013232)
1. Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing.
Gaber T; Brinkman ACK; Pienczikowski J; Diesing K; Damerau A; Pfeiffenberger M; Lang A; Ohrndorf S; Burmester GR; Buttgereit F; Hoff P
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013232
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of TAK1 and/or JAK can rescue impaired chondrogenic differentiation of human mesenchymal stem cells in osteoarthritis-like conditions.
van Beuningen HM; de Vries-van Melle ML; Vitters EL; Schreurs W; van den Berg WB; van Osch GJ; van der Kraan PM
Tissue Eng Part A; 2014 Aug; 20(15-16):2243-52. PubMed ID: 24547725
[TBL] [Abstract][Full Text] [Related]
3. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.
LaBranche TP; Jesson MI; Radi ZA; Storer CE; Guzova JA; Bonar SL; Thompson JM; Happa FA; Stewart ZS; Zhan Y; Bollinger CS; Bansal PN; Wellen JW; Wilkie DP; Bailey SA; Symanowicz PT; Hegen M; Head RD; Kishore N; Mbalaviele G; Meyer DM
Arthritis Rheum; 2012 Nov; 64(11):3531-42. PubMed ID: 22899318
[TBL] [Abstract][Full Text] [Related]
4. The Janus kinase inhibitor tofacitinib inhibits TNF-α-induced gliostatin expression in rheumatoid fibroblast-like synoviocytes.
Kawaguchi Y; Waguri-Nagaya Y; Tatematsu N; Oguri Y; Kobayashi M; Nozaki M; Asai K; Aoyama M; Otsuka T
Clin Exp Rheumatol; 2018; 36(4):559-567. PubMed ID: 29352846
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
[TBL] [Abstract][Full Text] [Related]
6. Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis.
Wei X; Wu J; Zhao G; Galdamez J; Lele SM; Wang X; Liu Y; Soni DM; Purdue PE; Mikuls TR; Goldring SR; Wang D
Mol Pharm; 2018 Aug; 15(8):3456-3467. PubMed ID: 29966420
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of microRNA-222 expression accelerates bone healing with enhancement of osteogenesis, chondrogenesis, and angiogenesis in a rat refractory fracture model.
Yoshizuka M; Nakasa T; Kawanishi Y; Hachisuka S; Furuta T; Miyaki S; Adachi N; Ochi M
J Orthop Sci; 2016 Nov; 21(6):852-858. PubMed ID: 27545451
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of JAK inhibitor on mechanical stress-induced protease expression by human articular chondrocytes.
Machida T; Nishida K; Nasu Y; Nakahara R; Ozawa M; Harada R; Horita M; Takeshita A; Kaneda D; Yoshida A; Ozaki T
Inflamm Res; 2017 Nov; 66(11):999-1009. PubMed ID: 28752178
[TBL] [Abstract][Full Text] [Related]
9. The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development.
Stalder R; Zhang B; Jean Wrobel L; Boehncke WH; Brembilla NC
Exp Dermatol; 2020 Jan; 29(1):71-78. PubMed ID: 31721311
[TBL] [Abstract][Full Text] [Related]
10. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
Hodge JA; Kawabata TT; Krishnaswami S; Clark JD; Telliez JB; Dowty ME; Menon S; Lamba M; Zwillich S
Clin Exp Rheumatol; 2016; 34(2):318-28. PubMed ID: 26966791
[TBL] [Abstract][Full Text] [Related]
11. Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
Mitchell TS; Moots RJ; Wright HL
Clin Exp Immunol; 2017 Aug; 189(2):250-258. PubMed ID: 28369741
[TBL] [Abstract][Full Text] [Related]
12. Role of janus kinase inhibitors in the treatment of alopecia areata.
Triyangkulsri K; Suchonwanit P
Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
[TBL] [Abstract][Full Text] [Related]
13. Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways.
Li CH; Xu LL; Jian LL; Yu RH; Zhao JX; Sun L; Du GH; Liu XY
Int Immunopharmacol; 2018 May; 58():136-144. PubMed ID: 29587202
[TBL] [Abstract][Full Text] [Related]
14. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
Lam C; Ferguson ID; Mariano MC; Lin YT; Murnane M; Liu H; Smith GA; Wong SW; Taunton J; Liu JO; Mitsiades CS; Hann BC; Aftab BT; Wiita AP
Haematologica; 2018 Jul; 103(7):1218-1228. PubMed ID: 29622655
[TBL] [Abstract][Full Text] [Related]
15. Effect of Janus kinase inhibition by tofacitinib on body composition and glucose metabolism.
Chikugo M; Sebe M; Tsutsumi R; Iuchi M; KIshi J; Kuroda M; Harada N; Nishioka Y; Sakaue H
J Med Invest; 2018; 65(3.4):166-170. PubMed ID: 30282855
[TBL] [Abstract][Full Text] [Related]
16. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes.
Srivastava A; Ståhle M; Pivarcsi A; Sonkoly E
Acta Derm Venereol; 2018 Aug; 98(8):772-775. PubMed ID: 29738047
[TBL] [Abstract][Full Text] [Related]
18. Hypoxic preconditioning of human mesenchymal stem cells overcomes hypoxia-induced inhibition of osteogenic differentiation.
Volkmer E; Kallukalam BC; Maertz J; Otto S; Drosse I; Polzer H; Bocker W; Stengele M; Docheva D; Mutschler W; Schieker M
Tissue Eng Part A; 2010 Jan; 16(1):153-64. PubMed ID: 19642854
[TBL] [Abstract][Full Text] [Related]
19. Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-κB signaling pathways.
Ibrahim SSA; Salama MA; Selima E; Shehata RR
Life Sci; 2020 Nov; 260():118261. PubMed ID: 32795539
[TBL] [Abstract][Full Text] [Related]
20. Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis.
Hamar A; Szekanecz Z; Pusztai A; Czókolyová M; Végh E; Pethő Z; Bodnár N; Gulyás K; Horváth Á; Soós B; Bodoki L; Bhattoa HP; Nagy G; Tajti G; Panyi G; Szekanecz É; Domján A; Hodosi K; Szántó S; Szűcs G; Szamosi S
Osteoporos Int; 2021 Aug; 32(8):1621-1629. PubMed ID: 33559714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
